December 14, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has received approval from the Drug Regulatory Authority of Pakistan (DRAP) for ADALIMUMAB, a biosimilar drug developed in collaboration with BioRay Biopharmaceuticals Co. Limited, China, the company's latest filing on the PSX showed today.
This marks the first locally manufactured Monoclonal antibody (mABs) in Pakistan, the notice reads.
The introduction of ADALIMUMAB to the market within the next 3-6 months is a strategic move aimed at providing high-quality, affordable biotechnology medicines to patients in Pakistan, it said.
The company said that this development aligns with its commitment to diversifying its product portfolio, thereby enhancing the quality of earnings and shareholders' value.
Copyright Mettis Link News
Posted on:2023-12-14T12:06:06+05:00
42107
